aspsirna0701 details

''''
ASPsiRNA information siRNA Id:aspsirna0701
siRNA Name: G9m
Mismatch information Wild siRNA (As strand 3'->5'):GGUUCUUUCGACUCUCGUC
ASP-siRNA (As strand 3'->5'):GGUUCUUUCGGCUCUCGUC
Mismatch position in siRNA: G9A(As),U19G(s)
Gene Information Gene Name Ataxin-1 (ATXN1)
Target Sequence (5'->3'):CACCAAGAAAGCTGAGAGCAGCCGGCT
Wild allele (5'->3'):CCAAGAAAGCUGAGAGCAG
Mutant allele (5'->3'):CCAAGAAAGCCGAGAGCAU
Position of siRNA on target gene: 1888-1906
Respective Gene/Protein Resources GenBank Accession:NM_000332.3
Cytogenic location:6p22.3
Chromosomal coordinates:6:16,299,342-16,761,720
UniProt ID:P0C7T5
HUGO ID:10548
Reference SNp(RefSNP): rs19392292
Disease/Mutation information Target Mutation: c.589_591CAG(36_38),p.Gln208_His209
Matation type/variant: Microsatellite
Mutation at gene level: NG_011571.1:g.438769_438771CAG(36_38)
Pathogenic status of mutation: Pathogenic
Disease:Spino Cerebellar Ataxia type-1 (SCA-1)
Clinical Resources ClinVar ID:8071
KEGG disease ID:H00063
OMIM ID: 302500
COSMIC: ATXN1
DECIPHER: ATXN1
GeneTests: ATXN1
ASP siRNA details Mutant allele (5'->3'): CCAAGAAAGCCGAGAGCAU
ASP-siRNA (As strand 3'->5'):GGUUCUUUCGGCUCUCGUC
Percentage efficacy of ASP-siRNA for mutant allele:0
Wild allele (5'->3'): CCAAGAAAGCUGAGAGCAG
ASP-siRNA (As strand 3'->5'):GGUUCUUUCGGCUCUCGUC
Percentage efficacy of ASP-siRNA for wild allele:24
Relative difference:-24
Wild siRNA details Wild allele (5'->3'): CCAAGAAAGCUGAGAGCAG
Wild siRNA (As strand 3'->5'):GGUUCUUUCGACUCUCGUC
Percentage efficacy of wild siRNA for wild allele:60
Wild allele (5'->3'): CCAAGAAAGCUGAGAGCAG
ASP-siRNA (As strand 3'->5'):GGUUCUUUCGGCUCUCGUC
Percentage efficacy of Wild sirna for mutant allele:15
Relative difference :45
General information Mismatch incorporated in siRNA/Target:siRNA
Cell-line used: Fibroblast
Experimental technique used: RT-PCR
Transfection method: Lipofectamine 2000
siRNA expression method: Metabion
Post-transfection duration: 72 hours
Concentration used:50nM
Reference:22397573
Delivery method:Transfection
Article title:An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.
Authors:Fiszer A, Olejniczak M, Switonski PM, Wroblewska JP, Wisniewska-Kruk J, Mykowska A, Krzyzosiak WJ.
Journal Reference:BMC Mol Biol. 2012 Mar 7;13:6. doi: 10.1186/1471-2199-13-6.